Table II.
Pathological features of cancer in radical prostatectomy specimens according to pre PSADT.
| Pathological stage, n (%) | Specimen Gleason score, n (%) | |||||||
|---|---|---|---|---|---|---|---|---|
| Pre-PSADT (months) | No of patients | pT2 | pT3a (EPE+) | pT3b (SV+) | pN+ (LV+) | 2–6 | 7 | 8–10 |
| Stable | 35 | 17 (49) | 14 (40) | 4 (11) | 0 | 8 (23) | 19 (54) | 8 (23) |
| <6 | 69 | 39 (57) | 21 (30) | 7 (10) | 2 (3) | 12 (17.4) | 37 (53.6) | 20 (29.0) |
| 6.0–11.9 | 42 | 26 (62.0) | 12 (28.5) | 3 (7.1) | 1 (2.4) | 12 (28.5) | 17 (40.5) | 13 (31.0) |
| 12.0–17.9 | 22 | 13 (59.1) | 8 (36.4) | 1 (4.5) | 0 | 8 (36.4) | 8 (36.4) | 6 (27.2) |
| 18.0–23.9 | 16 | 10 (62.5) | 5 (31.3) | 1 (6.2) | 0 | 4 (25.0) | 6 (37.5) | 6 (37.5) |
| ≥24.0 | 20 | 16 (80.0)a | 4 (20.0) | 0 | 0 | 11 (55.0)b | 7 (35.0) | 2 (10) |
a
P=0.047
b
P=0.003. Pre PSADT, preoperative prostate specific antigen doubling time; pT2, confined prostate cancer; pT3a (EPE+), extra prostatic extension positive; pT3b (SV+), seminal vesicle invasion positive; LV+, lymph node metastasis positive.